Eloxx Pharmaceuticals, Inc. Common Stock (ELOX)

• Market cap: $44M
• 1 day: 0.31%
• 5 days: 16.27%
• 1 month: 16.17%
• 3 months: 16.17%
• 6 months: 16.17%
• Year to date: 16.17%
• 1 year: 16.17%
• 5 years: 16.17%
• 10 years: 16.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Employees: 7